NASDAQ:EXEL

Exelixis Stock Forecast, Price & News

$22.09
-0.04 (-0.18 %)
(As of 06/18/2021 01:58 PM ET)
Add
Compare
Today's Range
$21.71
$22.31
50-Day Range
$22.06
$25.56
52-Week Range
$18.18
$27.35
Volume51,326 shs
Average Volume1.92 million shs
Market Capitalization$6.92 billion
P/E Ratio110.46
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.


Exelixis logo

About Exelixis

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

122nd out of 2,100 stocks

Biological Products, Except Diagnostic Industry

17th out of 198 stocks

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Exelixis (NASDAQ:EXEL) Frequently Asked Questions

Is Exelixis a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exelixis stock.
View analyst ratings for Exelixis
or view top-rated stocks.

What stocks does MarketBeat like better than Exelixis?

Wall Street analysts have given Exelixis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exelixis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Exelixis
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The biotechnology company earned $270.23 million during the quarter, compared to analysts' expectations of $265.04 million. Exelixis had a trailing twelve-month return on equity of 3.47% and a net margin of 6.28%. The business's revenue for the quarter was up 19.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.19 earnings per share.
View Exelixis' earnings history
.

How has Exelixis' stock been impacted by Coronavirus (COVID-19)?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EXEL stock has increased by 28.5% and is now trading at $22.25.
View which stocks have been most impacted by COVID-19
.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.15 billion-$1.25 billion, compared to the consensus revenue estimate of $1.22 billion.

What price target have analysts set for EXEL?

9 analysts have issued 1 year price targets for Exelixis' stock. Their forecasts range from $26.00 to $47.00. On average, they anticipate Exelixis' stock price to reach $34.75 in the next year. This suggests a possible upside of 56.2% from the stock's current price.
View analysts' price targets for Exelixis
or view top-rated stocks among Wall Street analysts.

Who are Exelixis' key executives?

Exelixis' management team includes the following people:
  • Dr. Stelios Papadopoulos Ph.D., Co-Founder & Independent Chairman (Age 73, Pay $98k)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 60, Pay $2.35M)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 53, Pay $1.06M)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 52, Pay $916.91k)
  • Dr. Gisela M. Schwab, Pres of Product Devel. & Medical Affairs and Chief Medical Officer (Age 64, Pay $1.4M)
  • Mr. Patrick J. Haley M.B.A., MBA, Exec. VP of Commercial (Age 45, Pay $801.65k)
  • Dr. Dana T. Aftab, Exec. VP of Bus. Operations
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 60)
  • Ms. Susan T. Hubbard, Exec. VP of Public Affairs & Investor Relations
  • Mr. Jonathan Berndt, VP of Sales

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.26%), Price T Rowe Associates Inc. MD (6.62%), Renaissance Technologies LLC (5.95%), JPMorgan Chase & Co. (3.63%), Meditor Group Ltd (3.61%) and Geode Capital Management LLC (1.25%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis
.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Assenagon Asset Management S.A., Point72 Asset Management L.P., Meditor Group Ltd, Sectoral Asset Management Inc, AQR Capital Management LLC, Massachusetts Financial Services Co. MA, and Scout Investments Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi.
View insider buying and selling activity for Exelixis
or view top insider-selling stocks.

Which institutional investors are buying Exelixis stock?

EXEL stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Stephens Investment Management Group LLC, Great Point Partners LLC, BlackRock Inc., Lazard Asset Management LLC, EULAV Asset Management, Seizert Capital Partners LLC, and Blair William & Co. IL.
View insider buying and selling activity for Exelixis
or or view top insider-buying stocks.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $22.25.

How much money does Exelixis make?

Exelixis has a market capitalization of $6.97 billion and generates $987.54 million in revenue each year. The biotechnology company earns $111.78 million in net income (profit) each year or $0.35 on an earnings per share basis.

How many employees does Exelixis have?

Exelixis employs 773 workers across the globe.

When was Exelixis founded?

Exelixis was founded in 1994.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

Where are Exelixis' headquarters?

Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda CA, 94502.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.